RESUMO
Severity of rosacea in populations is not well characterized. A validated self-assessment tool was used to study the relationship between rosacea severity and demographic factors. Subjects were adult patients with a clinical diagnosis of rosacea. Self-assessment severity scores were significantly higher in participants less than 60 years old (mean 3.43 ± 1.07) compared with those greater than or equal to 60 years old (mean 3.09 ± 1.13; P = .04). Self-assessment severity scores were significantly higher in men (3.6 ± 1.3) than women (3.2 ± 1.0; P = .04). The authors conclude that rosacea is more severe in men and younger patients.
Assuntos
Autoavaliação Diagnóstica , Rosácea/epidemiologia , Rosácea/terapia , Inquéritos e Questionários , Adulto , Distribuição por Idade , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Comorbidade , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Prevalência , Rosácea/diagnóstico , Autocuidado , Índice de Gravidade de Doença , Distribuição por Sexo , Fatores Sexuais , Fatores de Tempo , Adulto JovemRESUMO
BACKGROUND: Costs for psoriasis have increased in recent years, in part due to the introduction of biologic agents. OBJECTIVE: To identify the most common and most costly (from the payer perspective) drugs used in the treatment of psoriasis. METHODS: We analyzed patient data from a large claims-based database in order to identify the most common and most costly medications used in the treatment of psoriasis from 2010 to 2014. RESULTS: The three most common psoriasis medications, accounting for 81.1% of all psoriasis medications, were topical corticosteroids. The three most costly drugs, accounting for only 9.6% of all psoriasis medications, were biologics, accounting for 86% of the cost of psoriasis medications. CONCLUSIONS: Biologic agents are used far less commonly in the treatment of psoriasis than topical treatments. Despite the relatively small number of patients using biologic agents, biologics are responsible for a large proportion of the cost of psoriasis pharmacotherapy.
Assuntos
Produtos Biológicos/economia , Fármacos Dermatológicos/economia , Glucocorticoides/economia , Honorários por Prescrição de Medicamentos , Psoríase/tratamento farmacológico , Administração Tópica , Produtos Biológicos/uso terapêutico , Análise Custo-Benefício , Fármacos Dermatológicos/uso terapêutico , Glucocorticoides/uso terapêutico , Humanos , Psoríase/economiaRESUMO
Hypothyroidism is a common disease, and there may be a link between hypothyroidism and inflammatory skin disease. The purpose of this study is to assess whether hypothyroidism is more prevalent in psoriasis or rosacea patients. We utilized a large claims-based database to analyze rates of hypothyroidism in patients with psoriasis and rosacea compared to other patients with skin diseases. Participants were patients between 20-64 years of age with ICD-9 diagnosis codes for psoriasis, rosacea, and hypothyroidism. We found that rates of hypothyroidism in rosacea and psoriasis patients were similar to rates of hypothyroidism in those without rosacea or psoriasis.
Assuntos
Hipotireoidismo/epidemiologia , Psoríase/epidemiologia , Rosácea/epidemiologia , Adulto , Comorbidade , Bases de Dados Factuais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Prevalência , Estados Unidos/epidemiologia , Adulto JovemRESUMO
Hypothyroidism is a common disease, and there may be a link between hypothyroidism and inflammatory skin disease. The purpose of this study is to assess whether hypothyroidism is more prevalent in psoriasis or rosacea patients. We utilized a large claims-based database to analyze rates of hypothyroidism in patients with psoriasis and rosacea compared to other patients with skin diseases. Participants were patients between 20-64 years of age with ICD-9 diagnosis codes for psoriasis, rosacea, and hypothyroidism. We found that rates of hypothyroidism in rosacea and psoriasis patients were similar to rates of hypothyroidism in those without rosacea or psoriasis.